zk 200775 has been researched along with Brain Ischemia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
De Keyser, J; Diener, HC; Elting, JW; Hommel, M; Kaste, M; Lees, KR; Sulter, GA; Teelken, AW; Versavel, M | 1 |
De Keyser, J; Diener, HC; Hommel, M; Kaste, M; Lees, KR; Steiner, H; Versavel, M; Walters, MR | 1 |
2 trial(s) available for zk 200775 and Brain Ischemia
Article | Year |
---|---|
AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels.
Topics: Acute Disease; Aged; Area Under Curve; Biomarkers; Brain Ischemia; Dose-Response Relationship, Drug; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nerve Growth Factors; Neuroglia; Organophosphonates; Phosphopyruvate Hydratase; Quinoxalines; Receptors, AMPA; Regression Analysis; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Severity of Illness Index; Stroke; Treatment Outcome | 2002 |
The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Electrocardiography; Humans; Middle Aged; Organophosphonates; Patient Compliance; Quinoxalines; Receptors, AMPA; Stroke; Treatment Outcome | 2005 |